Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study.
暂无分享,去创建一个
[1] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[2] A. Kutikhin,et al. Development of calcific aortic valve disease: Do we know enough for new clinical trials? , 2019, Journal of molecular and cellular cardiology.
[3] Daniel E Forman,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.
[4] S. Larsson,et al. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study , 2019, European heart journal.
[5] B. Nordestgaard,et al. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population , 2019, Annals of neurology.
[6] B. Nordestgaard,et al. Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population. , 2019, Clinical chemistry.
[7] J. Lincoln,et al. The Genetic Regulation of Aortic Valve Development and Calcific Disease , 2018, Front. Cardiovasc. Med..
[8] A. Ravani,et al. Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments , 2018, Pharmacological research.
[9] B. Nordestgaard,et al. APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137 895 Individuals , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[10] B. Nordestgaard,et al. Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study. , 2018, Clinical chemistry.
[11] B. Nordestgaard. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. , 2017, Journal of the American College of Cardiology.
[12] Tanya M. Teslovich,et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.
[13] Eliot A Brinton,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[14] S. Larsson,et al. Overall and abdominal obesity and incident aortic valve stenosis: two prospective cohort studies , 2017, European heart journal.
[15] Daniel R. Lavage,et al. Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease , 2017, JAMA.
[16] M. Scartezini,et al. Positioning about the Flexibility of Fasting for Lipid Profiling , 2017, Arquivos brasileiros de cardiologia.
[17] G. Francis,et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. , 2016, The Canadian journal of cardiology.
[18] D. Gudbjartsson,et al. Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease , 2016, Nature Genetics.
[19] P. McFarlane,et al. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.
[20] F. Kronenberg,et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.
[21] Dermot F. Reilly,et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease , 2018 .
[22] Alexander E. Lopez,et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. , 2016, The New England journal of medicine.
[23] B. Nordestgaard. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.
[24] M. Reilly,et al. From Loci to Biology: Functional Genomics of Genome-Wide Association for Coronary Disease. , 2016, Circulation research.
[25] P. O'Malley,et al. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline , 2015, Annals of Internal Medicine.
[26] M. Dweck,et al. Calcification in Aortic Stenosis: The Skeleton Key. , 2015, Journal of the American College of Cardiology.
[27] B. Nordestgaard,et al. Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population. , 2015, The Journal of clinical endocrinology and metabolism.
[28] Vilmundur Gudnason,et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. , 2014, JAMA.
[29] Anette Varbo,et al. Triglycerides and cardiovascular disease , 2014, The Lancet.
[30] B. Nordestgaard,et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. , 2014, The New England journal of medicine.
[31] He Zhang,et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. , 2014, The New England journal of medicine.
[32] B. Nordestgaard,et al. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.
[33] Tanya M. Teslovich,et al. Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.
[34] B. Nordestgaard,et al. Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.
[35] B. Nordestgaard,et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.
[36] J. Després,et al. Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling , 2013, European journal of clinical investigation.
[37] Kathleen F. Kerr,et al. Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.
[38] B. Nordestgaard,et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.
[39] H. Schirmer,et al. The evolving epidemiology of valvular aortic stenosis. The Tromsø Study , 2012, Heart.
[40] P. Heidenreich,et al. The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality. , 2012, The Journal of heart valve disease.
[41] R. Eckel,et al. Triglycerides and Heart Disease: Still a Hypothesis? , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[42] P. Schnohr,et al. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow‐up , 2011, Journal of internal medicine.
[43] Moshe Levi,et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.
[44] J. Borén,et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.
[45] B. Nordestgaard,et al. Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population , 2011, Annals of neurology.
[46] B. Nordestgaard,et al. TRIB1 and GCKR Polymorphisms, Lipid Levels, and Risk of Ischemic Heart Disease in the General Population , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[47] K. Teo,et al. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.
[48] H. Hense,et al. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. , 2009, European heart journal.
[49] B. Nordestgaard,et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. , 2008, JAMA.
[50] J. Chambers,et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.
[51] G. Feuchtner,et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). , 2008, The American journal of cardiology.
[52] G. Watts,et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. , 2008, Clinical science.
[53] J. Després,et al. Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[54] B. Nordestgaard,et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.
[55] J. Gardin,et al. Burden of valvular heart diseases: a population-based study , 2006, The Lancet.
[56] R. Kronmal,et al. Features of the Metabolic Syndrome and Diabetes Mellitus as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis , 2006, Circulation.
[57] R. Prescott,et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.
[58] B. Nordestgaard,et al. Lipoprotein Lipase Mutations, Plasma Lipids and Lipoproteins, and Risk of Ischemic Heart Disease A Meta-Analysis , 1999 .
[59] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[60] Catherine M. Otto,et al. Clinical Factors Associated With Calcific Aortic Valve Disease , 1997 .
[61] C. Otto,et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[62] A. Gown,et al. Characterization of the Early Lesion of ‘Degenerative’ Valvular Aortic Stenosis: Histological and Immunohistochemical Studies , 1994, Circulation.
[63] J. Parks,et al. Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans. , 1993, Journal of lipid research.
[64] A G Babiker,et al. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. , 1991, Statistics in medicine.
[65] R. Norum,et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. , 1986, The Journal of clinical investigation.